Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase NA 1

Status

Recruiting 30Active not recruiting 23Completed 8Not yet recruiting 6Terminated 2

Sponsor Class

OTHER 6

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 5Sarcoma 1

Conditions

Carcinoma, Hepatocellular 5Neoplasm Metastasis 1Bone Neoplasms 1

Interventions

Specimen Handling 57Magnetic Resonance Spectroscopy 39Carboplatin 32Cyclophosphamide 29Gemcitabine 28Bevacizumab 24pembrolizumab 23Cisplatin 23Biopsy 23Paclitaxel 22Standard of Care 21Radiotherapy 21Drug Therapy 21fludarabine 20Injections 20Capecitabine 20venetoclax 19Oxaliplatin 19Nivolumab 18Interviews as Topic 17toripalimab 16Dexamethasone 16Blood Specimen Collection 16Radiosurgery 14tislelizumab 13cemiplimab 13anlotinib 13Azacitidine 13Pemetrexed 12Irinotecan 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Not yet recruiting × lenvatinib × 90 days × Clear all
NCT07619950 2026-06-02

EVERolimus and LenvAtinib Versus Everolimus for Bone Sarcoma

Yonsei University

Phase 2 Not yet recruiting
94 enrolled
Sarcoma

Bone Neoplasms

NCT07495579 2026-05-27

REVIVE

Asan Medical Center

Phase 2 Not yet recruiting
146 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT07535840 2026-04-17

A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular Carcinoma

Tongji Hospital

Phase NA Not yet recruiting
25 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT07537946 2026-04-17

Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer

Tongji Hospital

Phase 3 Not yet recruiting
400 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Neoplasm Metastasis

NCT07518706 2026-04-09

Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting
60 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT07475026 2026-03-16

A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence

Tianjin Medical University Cancer Institute and Hospital

Phase 3 Not yet recruiting
198 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡